

Detection of NDM-1-Positive *Aeromonas caviae* from Bacteremia by Using Whole-Genome Sequencing

Shuguang Xu¹, Jinjing Tu¹, Liang Zhang¹, Yinv Chen¹, Xiaoqi Dong¹, Xiaohui Chi^{2,*}, Hao Xu^{2,*}

¹Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, People's Republic of China; ²Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China

*These authors contributed equally to this work

Correspondence: Hao Xu; Xiaohui Chi, Email xuhao930523@163.com; chixiaohui@zju.edu.cn

Purpose: Nosocomial infections caused by New Delhi metallo- β -lactamase (NDM)-producing bacteria are prevalent worldwide. However, such diseases caused by NDM-producing *Aeromonas caviae* had never been reported. Our study aimed to elucidate the genomic characteristics of NDM-1-producing *A. caviae* isolated from hospital patients.

Methods: Bacterial genomic features and possible origins were assessed by whole-genome sequencing (WGS) and phylogenetic analysis. Subsequent investigations include antimicrobial susceptibility testing and multilocus sequence typing (MLST).

Results: We identified here two NDM-1-producing *A. caviae* isolates from bacteremia. Susceptibility testing showed that two isolates were multi-drug resistant and shared a similar resistance profile and were only sensitive to amikacin and trimethoprim/sulfamethoxazole. Both *A. caviae* isolates carry the carbapenem resistance gene *bla*_{NDM-1} and also have antibiotic resistance genes such as β -lactams, AmpC enzymes, macrolides, aminoglycosides, and quinolones. S1-PFGE and Southern blot analysis were negative. Whole-genome sequencing and comparative analysis revealed that these two isolates shared a close relationship.

Conclusion: To the best of our knowledge, this work describes the first detection of non-plasmid encoded *bla*_{NDM-1} in *A. caviae*. The *A. caviae* isolated in this study has a broad drug resistance spectrum. Phenotypic and molecular analysis indicated the two isolates belong to the same clone. Routine genomic surveillance of this species is now necessary to effectively curb the further dissemination of carbapenem-resistant bacteria in the region.

Keywords: *Aeromonas caviae*, New Delhi metallo- β -lactamase, whole-genome sequencing, SNP, phylogenetic analysis

Introduction

The Genus *Aeromonas* belongs to the *Aeromonadaceae*, and it is a group of Gram-negative bacteria widely distributed in the aquatic environment.^{1,2} However, *Aeromonas* can cause a wide range of diseases in humans and animals, and the main pathogenic species of clinical relevance are *Aeromonas hydrophila* and *Aeromonas caviae*.³ They are emerging opportunistic human pathogens that can cause host wound infections, gastrointestinal infections, and even bacteremia.^{4,5}

The prevalence of carbapenemase-resistant *Enterobacteriaceae* (CRE) has risen since the 2000s.⁶ New Delhi metallo- β -lactamase (NDM) is a type of metallo- β -lactamase (MBL) able to hydrolyze most β -lactams (including carbapenems).^{7,8} Since the isolation of NDM-1-producing *Klebsiella pneumoniae* strains in India in 2008, NDM-1 has been found in various species of *Enterobacteriaceae*, *Acinetobacter*, and *Pseudomonas*.^{9,10} Since then, NDM-1 has become widely popular around the world. Successful dissemination of carbapenemase-producing bacteria poses an enormous global public health challenge.^{11,12}

However, there is no detailed genomic information on *A. caviae* carrying *bla*_{NDM-1} has been reported. In this study, two *A. caviae* strains carrying *bla*_{NDM-1} were isolated from patients with sepsis. The two clinically derived strains were further characterized by whole-genome sequencing and phylogenetic analysis. To the best of our knowledge, this is the first report that describes the detection of NDM-1-producing *A. caviae*.

Materials and Methods

Sample Collection

Two carbapenem-resistant strains, HZ574 and HZ578, were isolated from two female patients with sepsis hospitalized in a tertiary hospital in Huzhou, China. Bacterial species were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) (Bruker, Bremen, Germany). In addition, High throughput ANI analysis is used to compare the whole genome sequencing results to reveal distinct species of *Aeromonadaceae* (Figure S1). The carbapenemase genes (*bla*_{KPC}, *bla*_{NDM}, *bla*_{OXA-48}, *bla*_{VIM} and *bla*_{IMP}) were identified by polymerase chain reaction (PCR)¹³ (Table S1).

Antibiotic Susceptibility Testing

Minimum inhibitory concentrations (MICs) were determined by VITEK 2 system with AST-GN16 panel.¹⁴ The results were interpreted using European Committee on Antimicrobial Susceptibility Testing breakpoints, version 6.0, and Clinical and Laboratory Standards Institute document M100-S25.

Plasmid Characterization and Conjugation Assay

The number and size of the plasmid of the two isolates were characterized by the S1 Nuclease-Pulsed Field Gel Electrophoresis (S1-PFGE).¹⁵ Briefly, DNA plugs were digested using S1 Nase restriction enzyme (Takara Bio Inc., Kyoto, Japan) for 30 minutes. S1-PFGE was undertaken on a CHEF-DR III (Bio-Rad, Hercules, CA, USA) using the following parameters: running time 16 hours, temperature 14 °C, field strength 6 V/cm², angles 120°, initial pulse time 2.2 s, final pulse time 63.8 s. The location of *bla*_{NDM-1} was confirmed by Southern blotting and hybridization with a digoxigenin-labelled *bla*_{NDM-1} probe using DIG-High Prime DNA Labeling and Detection Starter Kit II (Roche Diagnostics). Plasmid conjugation experiments were performed by mating *E. coli* J53/EC600 as the recipient strain. Transconjugants were selected on agar (OXOID, Hampshire, UK) medium at a concentration of 200 mg/L sodium azide and two mg/L meropenem. Finally, MALDI-TOF-MS was used to identify transconjugants, and the target gene was verified by PCR. The location and size of plasmids were characterized by S1-PFGE as described previously.

Whole-Genome Sequencing

Whole-genome sequencing (WGS) was performed by Novo Gene Co., Ltd. Beijing, China, using the Illumina HiSeq (Illumina, San Diego, California) platform for all isolates. Alignment of antimicrobial resistance genes was performed through the ResFinder platform (<https://cge.cbs.dtu.dk/services/ResFinder/>). Multilocus sequence typing (MLST) was performed on bacteria using the website (<https://cge.cbs.dtu.dk/services/MLST/>). After annotating the strains using Prokka (rapid prokaryotic genome annotation), the genetic environment of carbapenemase encoding genes was characterized using Easyfig 2.2.3. Virulence genes were identified by blasting the VFDB database (<http://www.mgc.ac.cn/VFs/main.htm>).

Phylogenetic Reconstruction and Analysis

Thirty complete *A. caviae* genomes were downloaded from the National Center for Biotechnology Information (NCBI) for phylogenetic analysis (Table S2). Snippy (rapid haploid variant calling and core genome alignment) was used to compare genomic differences between strains.¹⁶ The alignment file was filtered from variants with elevated densities of base substitutions as putative recombination events by Gubbins version 2.4.1.¹⁷ The filtered core-genome alignment file was used to construct a maximum likelihood tree using FastTree with the GTR+CAT model.

Isolate	MIC (mg/L) ^a										
	AMC	TZP	CAZ	CRO	CPM	ETP	IPM	AMK	LVX	TGC	SXT
HZ574	32	128	64	64	16	8	16	2	8	8	20
HZ578	32	128	32	64	16	8	8	2	8	4	20

Abbreviations: AMC, amoxicillin/clavulanic acid; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; CPM, cefepime; ETP, ertapenem; IPM, imipenem; AMK, amikacin; LVX, levofloxacin; TE, tetracycline; TGC, tigecycline; SXT, trimethoprim/sulfamethoxazole.

The whole-genome sequences of the *A. caviae* were submitted to GenBank under the following BioProject numbers: PRINA799930

Antibiotic Resistance Signature of *A. caviae*

Antimicrobial Resistance Genes

[illegible]

2837




Figure 2 S1 Nuclease-pulsed field gel electrophoresis (SI-PFGE) and southern blot. The number and size of the plasmid of the two isolates were characterized by the S1 Nuclease-pulsed field gel electrophoresis (SI-PFGE).

Virulence Genes

The results of the alignment of virulence genes are shown in [Figure 1](#). The virulence genes carried by HZ574 and HZ578 are related genes of the Type VI secretion system, Tap type IV pili, Polar flagella, twitching ATPase, and Hemolysin A. The strains downloaded from NCBI mainly carried secretion pathway protein (83.33%) and related genes of Polar flagella (100%).

Molecular Characteristics of *A. caviae*

MLST typing analysis of 32 *A. caviae* strains showed that only six strains had a known ST type, including ST141, ST313, and ST645 ([Figure 1](#)). S1-PFGE and Southern blot demonstrated that the *bla*_{NDM-1} gene is not carried by plasmid in isolates HZ574 and HZ578 ([Figure 2](#)). Moreover, two isolates were both negative for genes of plasmid typing replicon. These results indicated that *bla*_{NDM-1} gene is chromosome encoded in these two isolates. Phylogenetic analysis of all the strains showed that HZ574 and HZ578 were located in the same clade and had a close relationship with GCA_000959705 from Brazil ([Figure 1](#)). Moreover, the *bla*_{NDM-1} genes of HZ574 and HZ578 share the same genetic environment ([Figure 3](#)).

Discussion

With the widespread of carbapenemase-producing bacteria, *bla*_{NDM-1} has been detected in various bacteria worldwide, but there is no detailed genomic information on *A. caviae* carrying *bla*_{NDM-1} has been reported.^{10,18} In this study, two




Figure 3 The genetic environment of the *bla*_{NDM-1} gene in *A. caviae* was isolated from clinical sources. The arrows represent the direction of transcription. The red open reading frame (ORF) indicates the *bla*_{NDM-1} gene, the yellow ORF indicates the mobile element, the green ORF indicates enzymes, and the grey ORF indicates other genes or genes of unknown function.

strains of *A. caviae* carrying NDM-1 were isolated from patients. The two clinically derived strains were characterized by genome and phylogenetic analysis using whole-genome sequencing technology.

The study results on the resistance of *A. caviae* showed that *A. caviae* is resistant to penicillin and first-generation cephalosporins.^{19,20} However, it is susceptible to monobactams, carbapenems, third- and fourth-generation cephalosporins, aminoglycosides, and fluoroquinolones.²¹ As *A. caviae* has been isolated, its resistance spectrum has changed, most notably due to the presence of genes encoding the production of β -lactamases, resulting in increased resistance to β -lactam antimicrobials.²² The HZ574 and HZ578 isolates in this study were both resistant to ertapenem and imipenem. The results of whole-genome sequencing showed that HZ574 and HZ578 carried *bla*_{NDM-1}, indicating that the resistant phenotype was consistent with the genotype. In addition, HZ574 and HZ578 also carry antibiotic resistance genes such as β -lactams, AmpC enzymes, macrolides, aminoglycosides, quinolones and have multidrug-resistant phenotypes.²³ Notably, *A. caviae* in this study had a broader spectrum of resistance compared with *A. caviae* available at NCBI (Figure 1).

The virulence potential and pathogenic mechanism of *A. caviae* remain unclear.²⁴ Through the analysis of virulence genes, we found that HZ574 and HZ578 in this study contained many kinds of virulence genes, such as Type VI secretion system, Tap type IV pili, Polar flagella, twitching ATPase, Hemolysin A. These virulence factors can help bacteria attach to the host surface, cause host cell and tissue damage, evade the host immune response, and allow bacteria adhere to the cell surface to form biofilms.^{25,26} The strains downloaded from NCBI mainly carried secretion pathway protein (83.33%) and related genes of Polar flagella (100%), suggesting that *A. caviae* in this study may have a more substantial virulence potential (Figure 1).²⁷

The phylogenetic analysis of HZ574 and HZ578 and the complete *A. caviae* genome downloaded from NCBI showed three evolutionary clones of *A. caviae*. HZ574 and HZ578 were related in the second clone (Figure 1). This is probably due to the isolation of these two strains being in the same period of time, and both patients were hospitalized in the same hospital. Phylogenetic analysis showed that HZ574 and HZ578 were located in the same branch as GCA_000959705 from Brazil. We speculate that HZ574 and HZ578 belong to the same clone, although two isolates were recovered from different patients. Analysis of the gene-environment of *bla*_{NDM-1} found that there are mobile transfer elements around *bla*_{NDM-1}, which increases the risk of spreading the drug resistance gene, and also suggests that we should carry out routine testing and appropriately treat patients (Figure 3).²⁸ This work may have important implications on the transmission of *bla*_{NDM-1} gene in the hospital. We emphasize the importance of improved multisectoral surveillance for carbapenemase-producing isolates, which may contribute to the spread of antimicrobial resistance genes in clinical settings and communities.

Conclusions

We report the *A. caviae* carrying *bla*_{NDM-1} from bacteremia. The study demonstrated the genomic characteristics of *A. caviae* carrying *bla*_{NDM-1} by whole-genome sequencing. The *A. caviae* isolated in this study has a broad drug

resistance spectrum, and the virulence genes carried by the strains pose challenges to clinical treatment. Routine genomic surveillance of this clone is now necessary to effectively curb the dissemination of drug-resistant bacteria in this region.

Ethical Statement

The study protocol was reviewed, approved by and carried out following the recommendations of the Ethics Committee of the Ningbo Medical Center Lihuili Hospital. Written informed consents were obtained from patients. The study complies with the Declaration of Helsinki.

Funding

This project was supported by Zhejiang Medical and Health Science and Technology Project (No. 2022KY1090) and the National Natural Science Foundation of China (No. 82072314).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Fernandez-Bravo A, Figueras MJ. An update on the genus *Aeromonas*: taxonomy, epidemiology, and pathogenicity. *Microorganisms*. 2020;8(1):129. doi:10.3390/microorganisms8010129
2. Castelo-Branco DS, Silva AL, Monteiro FO, et al. *Aeromonas* and *Plesiomonas* species from scarlet ibis (*Eudocimus ruber*) and their environment: monitoring antimicrobial susceptibility and virulence. *Antonie Leeuwenhoek*. 2017;110(1):33–43. doi:10.1007/s10482-016-0771-9
3. Rosso F, Cedano JA, Parra-Lara LG, et al. Emerging carbapenem-resistant *Aeromonas* spp. infections in Cali, Colombia. *Braz J Infect Dis*. 2019;23(5):336–342. doi:10.1016/j.bjid.2019.08.005
4. Kitagawa H, Ohge H, Yu L, et al. *Aeromonas dhakensis* is not a rare cause of *Aeromonas* bacteremia in Hiroshima, Japan. *J Infect Chemother*. 2020;26(2):316–320. doi:10.1016/j.jiac.2019.08.020
5. De Silva L, Wickramanayake M, Heo GJ. Virulence and antimicrobial resistance potential of *Aeromonas* spp. associated with shellfish. *Lett Appl Microbiol*. 2021;73(2):176–186. doi:10.1111/lam.13489
6. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis*. 2013;13(9):785–796. doi:10.1016/S1473-3099(13)70190-7
7. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. *Trends Microbiol*. 2011;19(12):588–595. doi:10.1016/j.tim.2011.09.005
8. Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among Carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. *Front Cell Infect Microbiol*. 2020;10:314. doi:10.3389/fcimb.2020.00314
9. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis*. 2010;10(9):597–602. doi:10.1016/S1473-3099(10)70143-2
10. Villacis JE, Bovera M, Romero-Alvarez D, et al. NDM-1 carbapenemase in *Acinetobacter baumannii* sequence type 32 in Ecuador. *New Microbes New Infect*. 2019;29:100526. doi:10.1016/j.nmni.2019.100526
11. Bassetti M, Giacobbè DR, Giamarellou H, et al. Management of KPC-producing *Klebsiella pneumoniae* infections. *Clin Microbiol Infect*. 2018;24(2):133–144. doi:10.1016/j.cmi.2017.08.030
12. Falcone M, Daikos GL, Tiseo G, et al. Efficacy of Ceftazidime-avibactam plus Aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing Enterobacteriales. *Clin Infect Dis*. 2021;72(11):1871–1878. doi:10.1093/cid/ciaa586
13. Zheng B, Zhang J, Ji J, et al. Emergence of Raoultella ornithinolytica coproducing IMP-4 and KPC-2 Carbapenemases in China. *Antimicrob Agents Chemother*. 2015;59(11):7086–7089. doi:10.1128/AAC.01363-15
14. Lellouche J, Schwartz D, Elmaleh N, et al. Combining VITEK(R) 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility. *Clin Microbiol Infect*. 2019;25(6):711–716. doi:10.1016/j.cmi.2018.09.014
15. Xu H, Wang X, Yu X, et al. First detection and genomics analysis of KPC-2-producing *Citrobacter* isolates from river sediments. *Environ Pollut*. 2018;235:931–937. doi:10.1016/j.envpol.2017.12.084
16. Stohr J, Kluytmans-van den Bergh MFQ, Weterings V, Rossen JWA, Kluytmans J. Distinguishing bla KPC gene-containing IncF plasmids from epidemiologically related and unrelated Enterobacteriaceae based on short- and long-read sequence data. *Antimicrob Agents Chemother*. 2021;65(6). doi:10.1128/AAC.00147-21
17. Croucher NJ, Page AJ, Connor TR, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res*. 2015;43(3):e15. doi:10.1093/nar/gku1196
18. Liang Z, Pang J, Hu X, et al. Low prevalence of mcr-1 among clinical Enterobacteriaceae isolates and co-transfer of mcr-1 and blaNDM-1 from separate donors. *Microb Drug Resist*. 2021;27(4):476–484. doi:10.1089/mdr.2020.0212
19. Janda JM, Abbott SL. The genus *Aeromonas*: taxonomy, pathogenicity, and infection. *Clin Microbiol Rev*. 2010;23(1):35–73. doi:10.1128/CMR.00039-09
20. Vila J, Ruiz J, Gallardo F, et al. *Aeromonas* spp. and traveler's diarrhea: clinical features and antimicrobial resistance. *Emerg Infect Dis*. 2003;9(5):552–555. doi:10.3201/eid0905.020451
21. Codjoe FS, Donkor ES. Carbapenem resistance: a review. *Med Sci*. 2017;6(1):1.
22. Dias C, Serra CR, Simoes LC, Simoes M, Martinez-Murcia A, Saavedra MJ. Extended-spectrum beta-lactamase and carbapenemase-producing *Aeromonas* species in wild animals from Portugal. *Vet Rec*. 2014;174(21):532. doi:10.1136/vr.101803

23. Chi X, Berglund B, Zou H, et al. Characterization of clinically relevant strains of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* occurring in environmental sources in a rural area of China by using whole-genome sequencing. *Front Microbiol.* 2019;10. doi:10.3389/fmicb.2019.00211
24. Silva L, Leal-Balbino TC, Melo BST, et al. Genetic diversity and virulence potential of clinical and environmental *Aeromonas* spp. isolates from a diarrhea outbreak. *BMC Microbiol.* 2017;17(1):179. doi:10.1186/s12866-017-1089-0
25. Tomas JM. The main *Aeromonas* pathogenic factors. *ISRN Microbiol.* 2012;2012:256261. doi:10.5402/2012/256261
26. Batra P, Mathur P, Misra MC. *Aeromonas* spp.: an emerging nosocomial pathogen. *J Lab Physicians.* 2016;8(1):1–4. doi:10.4103/0974-2727.176234
27. Hofer E, Reis CM, Theophilo GN, Cavalcanti VO, Lima NV, Henriques Mde F. [Aeromonas associated with an acute diarrhea outbreak in Sao Bento do Una, Pernambuco]. *Rev Soc Bras Med Trop.* 2006;39(2):217–220. Swedish. doi:10.1590/S0037-86822006000200016
28. Kim JS, Jin YH, Park SH, et al. Horizontal transfer of blaNDM-1-carrying IncX3 plasmid between carbapenem-resistant Enterobacteriaceae in a single patient. *J Infect.* 2020;81(5):816–846. doi:10.1016/j.jinf.2020.07.013

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>